Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications
Source abstract
Abstract
Abstract Although considerable efforts have been conducted to diagnose, improve, and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. Perhaps the best hope for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase the current understanding of tumor biology, and will allow nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Owing to their intrinsic physicochemical characteristics, nanostructures (NSs) are valuable tools that have received much attention in nanoimaging. Consequently, rationally designed NSs have been successfully employed in cancer imaging for targeting cancer‐specific or cancer‐associated molecules and pathways. This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membrane‐coated nanoparticles, tumor cell‐derived extracellular vesicles, circulating tumor cells, cell‐free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology‐based imaging probes in the future.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Proteomics Research Centre Tabriz University of Medical Sciences Tabriz 5165665811 Iran
Department of Medical Nanotechnology Faculty of Advanced Medical Sciences Tabriz University of Medical Sciences Golgasht Street Tabriz 516615731 Iran
Student Research Committee Tabriz University of Medical Sciences Tabriz 5165666532 Iran
Stem Cell Research Center Tabriz University of Medical Sciences Tabriz 5165665621 Iran
Drug Applied Research Center Tabriz University of Medical Sciences Tabriz 6581151656 Iran
U‐BiND Systems Laboratory Department of Pharmaceutical Sciences Wayne State University Detroit MI 48201 USA
Northville High School Northville MI 48168 USA
Department of Biomedical Engineering Wayne State University Detroit MI 48202 USA
Wellman Center for Photomedicine Massachusetts General Hospital Harvard Medical School Boston MA 02114 USA
Laser Research Centre Faculty of Health Science University of Johannesburg Doornfontein Johannesburg 2028 South Africa
Funding
Tabriz University of Medical Sciences · National Institutes of Health
References (100+)
Show source-provided references
1. 10.1038/nmat387710.1038/nmat3877 ↗
2. 10.1038/nm.391510.1038/nm.3915 ↗
3. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
4. 10.1067/mcp.2001.11398910.1067/mcp.2001.113989 ↗
5. 10.1021/acs.chemrev.6b0007310.1021/acs.chemrev.6b00073 ↗
6. 10.1002/adfm.20160352410.1002/adfm.201603524 ↗
7. 10.1038/s41551-016-001010.1038/s41551-016-0010 ↗
8. 10.1038/natrevmats.2017.1410.1038/natrevmats.2017.14 ↗
9. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
10. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
11. 10.1038/nrc109310.1038/nrc1093 ↗
12. 10.1080/1061186070153958410.1080/10611860701539584 ↗
13. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
14. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
15. Skinner S. A. · Cancer Res. · 1990 · 50 · 2411
16. 10.1097/CAD.0b013e32834a455410.1097/CAD.0b013e32834a4554 ↗
17. 10.1038/nmat378010.1038/nmat3780 ↗
18. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
19. Maeda H. · Crit. Rev. Ther. Drug Carrier Syst. · 1989 · 6 · 193
20. 10.1166/nnl.2010.105910.1166/nnl.2010.1059 ↗
21. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
22. 10.1016/j.jconrel.2012.11.01710.1016/j.jconrel.2012.11.017 ↗
23. 10.1021/acsnano.5b0132410.1021/acsnano.5b01324 ↗
24. 10.1021/acs.nanolett.7b0002110.1021/acs.nanolett.7b00021 ↗
25. 10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗
26. 10.1038/sj.neo.790003710.1038/sj.neo.7900037 ↗
27. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
28. Nabil G. · Drug Discovery Today · 2018
29. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
30. 10.1016/j.heliyon.2018.e0107110.1016/j.heliyon.2018.e01071 ↗
31. 10.1038/ncomms683410.1038/ncomms6834 ↗
32. 10.1016/j.cmet.2005.05.00110.1016/j.cmet.2005.05.001 ↗
33. 10.1158/1078-0432.CCR-05-166410.1158/1078-0432.CCR-05-1664 ↗
34. 10.2967/jnumed.110.07566310.2967/jnumed.110.075663 ↗
35. 10.1021/ol102975t10.1021/ol102975t ↗
36. 10.1021/ja409578w10.1021/ja409578w ↗
37. 10.1021/cr300358b10.1021/cr300358b ↗
38. 10.1038/nrc70410.1038/nrc704 ↗
39. 10.1021/acs.nanolett.6b0026210.1021/acs.nanolett.6b00262 ↗
40. Lv Z. · ACS Appl. Mater. Interfaces · 2018
41. 10.1038/s41467-017-01951-010.1038/s41467-017-01951-0 ↗
42. 10.1021/acsnano.7b0473710.1021/acsnano.7b04737 ↗
43. 10.1038/nrc147810.1038/nrc1478 ↗
44. 10.1158/0008-5472.CAN-12-279610.1158/0008-5472.CAN-12-2796 ↗
45. 10.1016/j.lfs.2012.01.00810.1016/j.lfs.2012.01.008 ↗
46. 10.1039/c2cc31697h10.1039/c2cc31697h ↗
47. 10.1021/acs.molpharmaceut.5b0043010.1021/acs.molpharmaceut.5b00430 ↗
48. 10.1038/ncomms1499810.1038/ncomms14998 ↗
49. 10.1038/nm.185410.1038/nm.1854 ↗
50. 10.1038/nmat381910.1038/nmat3819 ↗
51. 10.1038/nnano.2016.7210.1038/nnano.2016.72 ↗
52. 10.1002/adhm.20150090810.1002/adhm.201500908 ↗
53. 10.1016/j.cardiores.2005.12.00210.1016/j.cardiores.2005.12.002 ↗
54. 10.1038/nrc74510.1038/nrc745 ↗
55. 10.3892/ol.2011.39110.3892/ol.2011.391 ↗
56. Schmalfeldt B. · Clin. Cancer Res. · 2001 · 7 · 2396
57. 10.1146/annurev.cellbio.17.1.46310.1146/annurev.cellbio.17.1.463 ↗
58. 10.1142/9781783267231_000310.1142/9781783267231_0003 ↗
59. 10.1038/9027310.1038/90273 ↗
60. 10.1016/j.jconrel.2015.11.01210.1016/j.jconrel.2015.11.012 ↗
61. 10.1371/journal.pone.019204710.1371/journal.pone.0192047 ↗
62. 10.1016/j.addr.2016.09.00610.1016/j.addr.2016.09.006 ↗
63. 10.18632/oncotarget.1361510.18632/oncotarget.13615 ↗
64. 10.1007/s10555-013-9420-110.1007/s10555-013-9420-1 ↗
65. 10.1038/ncomms438810.1038/ncomms4388 ↗
66. 10.1016/j.humpath.2013.03.00610.1016/j.humpath.2013.03.006 ↗
67. 10.1007/s10585-015-9754-x10.1007/s10585-015-9754-x ↗
68. Malik G. · Cancer Res. · 2010 · 0008
69. 10.1039/C6TB02008A10.1039/C6TB02008A ↗
70. 10.1158/0008-5472.CAN-07-143610.1158/0008-5472.CAN-07-1436 ↗
71. 10.1038/ncomms898410.1038/ncomms8984 ↗
72. 10.1038/s41467-017-00741-y10.1038/s41467-017-00741-y ↗
73. 10.7150/thno.1516910.7150/thno.15169 ↗
74. 10.1038/nm.193810.1038/nm.1938 ↗
75. 10.1038/cdd.2014.21610.1038/cdd.2014.216 ↗
76. 10.1016/j.bbamcr.2008.01.03010.1016/j.bbamcr.2008.01.030 ↗
77. Boersma H. H. · J. Nucl. Med. · 2005 · 46 · 2035
78. 10.1038/nchem.192010.1038/nchem.1920 ↗
79. 10.7150/thno.3556010.7150/thno.35560 ↗
80. 10.18632/oncotarget.1699410.18632/oncotarget.16994 ↗
81. 10.1097/01.mnm.0000189778.60496.3010.1097/01.mnm.0000189778.60496.30 ↗
82. Lahorte C. · Nucl. Med. Commun. · 2003 · 24 · 871
83. Ke S. · J. Nucl. Med. · 2004 · 45 · 108
84. 10.1016/S0092-8674(00)80108-710.1016/S0092-8674(00)80108-7 ↗
85. 10.1083/jcb.153.3.54310.1083/jcb.153.3.543 ↗
86. 10.1038/nrc72410.1038/nrc724 ↗
87. 10.1021/nn204625e10.1021/nn204625e ↗
88. 10.1016/j.biomaterials.2017.05.03710.1016/j.biomaterials.2017.05.037 ↗
89. 10.1158/1078-0432.CCR-06-131310.1158/1078-0432.CCR-06-1313 ↗
90. 10.1038/nature0418610.1038/nature04186 ↗
91. 10.1200/JCO.2002.10.08810.1200/JCO.2002.10.088 ↗
92. 10.1200/JCO.2005.06.08110.1200/JCO.2005.06.081 ↗
93. 10.1016/S1535-6108(02)00051-X10.1016/S1535-6108(02)00051-X ↗
94. 10.1038/nrc240310.1038/nrc2403 ↗
95. 10.1007/BF0066596010.1007/BF00665960 ↗
96. 10.1158/0008-5472.671.65.310.1158/0008-5472.671.65.3 ↗
97. 10.2967/jnumed.107.04130110.2967/jnumed.107.041301 ↗
98. 10.2967/jnumed.111.09283310.2967/jnumed.111.092833 ↗
99. 10.1016/j.nano.2014.12.01110.1016/j.nano.2014.12.011 ↗
100. 10.1093/jnci/94.19.148410.1093/jnci/94.19.1484 ↗